The IP6K2 Knockout HeLa Polyclonal Cells product offers a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the IP6K2 gene in HeLa cells. This loss-of-function model enables studies on inositol pyrophosphate signaling, apoptosis, and migration without single-cell clonal selection, retaining population heterogeneity for robust experiments.
HeLa cells are an HPV18-positive cervical adenocarcinoma-derived epithelial cell line that has served as a cornerstone of cancer research for decades. They exhibit robust in vitro growth, well-characterized genomics, and high transfection efficiency, making them an optimal host for CRISPR-based gene disruption studies. Their established role in dissecting oncogenic signaling pathways ensures that findings from this knockout model can be contextualized within a vast body of existing literature.
IP6K2 encodes a kinase that synthesizes 5-IP7, a second messenger that inhibits Akt by preventing its membrane recruitment, thereby promoting p53-dependent apoptosis and suppressing cell migration. Upstream, IP6K2 is regulated by TP53 and cellular stress signals including DNA damage and oxidative stress. Downstream, it interacts with the CRL4-CSN ubiquitin ligase complex (cullin 4A/B and COP9 signalosome subunit CSN1), linking inositol phosphate metabolism to protein degradation and apoptosis. Consequently, IP6K2 sits at a nexus integrating p53, Akt/mTOR, and autophagy pathways.
In HeLa cervical carcinoma cells, IP6K2 knockout is expected to reduce 5-IP7 levels, relieving Akt inhibition and enhancing survival and migratory phenotypes. This disruption of the IP6K2-p53-Akt axis may foster oncogenic traits, making the model valuable for deciphering apoptosis resistance, metabolic shifts, and metastatic mechanisms in cervical adenocarcinoma. The polyclonal format ensures observed effects reflect a diverse cell pool, strengthening generalizability.
Researchers can employ this IP6K2 polyclonal knockout model to investigate the role of inositol pyrophosphates in cancer biology, validate IP6K2 as a therapeutic target in cervical carcinoma, and dissect the molecular crosstalk between apoptosis, autophagy, and cell migration. Common assays include Western blotting for total and phospho-Akt (Ser473), Annexin V/propidium iodide apoptosis detection, Transwell migration and Matrigel invasion assays, cell viability under nutlin-3 or other stressors, liquid chromatography-mass spectrometry for IP7 quantification, and immunofluorescence labeling of focal adhesion proteins. These experiments can illuminate how dysregulated inositol phosphate metabolism drives oncogenesis. For further technical support, please contact Ascent Research.
